** Shares of drug developer Altimmune ALT.O rose nearly 3% in extended trading before paring gains
** Company says that it is planning to test its experimental weight-loss drug, pemvidutide, as a treatment for alcohol use disorder and alcohol-associated liver disease
** Plans to begin a mid-stage trial in alcohol use disorder for pemvidutide in Q2 and another mid-stage trial for alcohol-related liver disease in Q3
** Co's drug, pemvidutide, has shown to help patients reduce their weight by 15.6% on average in a mid-stage trial
** As of the last close, stock down 27.9% YTD
(Reporting by Pooja Menon in Bengaluru)
((Pooja.Menon@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.